drugset / Trial / NCT05531968
Treatment of Moderate to Severe Glabellar Lines (BMI2006)
RandomizedParallel-groupTriple-blindTreatment
Summary
A multicenter, double-blind, randomized, parallel design, active control, phase 3 clinical trial to evaluate the efficacy and safety of 100 units of BMI 2006 and Botox® in adult patients in need of moderate or severe glabellar lines
Timeline
- Start
- 2021-02-09
- Primary completion
- 2021-08-10
- Completion
- 2021-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMI2006 | Unknown | 20 iu | Intramuscular |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | Intramuscular |
Indications
No indication recorded.